Korean Circ J.  2019 Apr;49(4):353-360. 10.4070/kcj.2018.0281.

Acute Hemodynamic Changes after Single Administration of Udenafil in Pulmonary Arterial Hypertension: a Phase IIa Study

• Chang SA
• Kim HK
• Chang HJ
• Kim DK

• KMID: 2441139
• DOI: http://doi.org/10.4070/kcj.2018.0281

Abstract

BACKGROUND AND OBJECTIVES
Udenafil, a new phosphodiesterase-5 inhibitor (PDE5i), has been used to treat erectile dysfunction. Given the proven benefit of PDE5i in pulmonary arterial hypertension (PAH), we evaluated serial hemodynamic changes after single udenafil administration to determine the appropriate therapeutic dose.
METHODS
Eighteen patients were randomly allocated into one of 3 groups: placebo, udenafil 50 mg (U50), and udenafil 100 mg (U100). Diagnosis for inclusion was idiopathic PAH or PAH associated with connective tissue disease. Patients with any contraindication to PDE5i, and/or PDE5i treatment in the past 1 month were excluded. Continuous hemodynamic monitoring was performed by placing a Swan-Ganz catheter. Information on cardiac index (CI), mean pulmonary arterial pressure (mPAP), mean systemic arterial pressure (mSAP), pulmonary arterial wedge pressure (PAWP), and pulmonary vascular resistance index (PVRI) was obtained for 4 hours after drug administration.
RESULTS
The mPAP significantly decreased in both the U50 and U100 (−11 mmHg and −8 mmHg from baseline, respectively, p < 0.1). The mSAP also decreased in both U50 and U100; however, the decrease was greater in the U100 (Δ=−8.5 mmHg and Δ=−14.0 mmHg). CI increased in the U50, but decreased in the U100. Although PVRI decreased in both, statistical significance was only achieved in the U50 compared to placebo. PAWP was stable during monitoring. U50 had at least 4 hour-effect after administration. Only 2 patients with U100 experienced mild adverse events.
CONCLUSIONS
This is the first demonstration of the acute hemodynamic changes induced by udenafil. U50 is considered an optimal dose for treating PAH with more than 4-hour treatment effect. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01553721.

Keyword

Hypertension, Pulmonary; Phosphodiesterase 5 inhibitors; Hemodynamic monitoring

MeSH Terms

Arterial Pressure
Catheters
Connective Tissue Diseases
Cyclic Nucleotide Phosphodiesterases, Type 5
Diagnosis
Erectile Dysfunction
Hemodynamics*
Humans
Hypertension*
Hypertension, Pulmonary
Male
Phosphodiesterase 5 Inhibitors
Pulmonary Wedge Pressure
Vascular Resistance
Cyclic Nucleotide Phosphodiesterases, Type 5
Phosphodiesterase 5 Inhibitors

Figure

• 

  Figure 1 Changes in major hemodynamic parameters according to time. (A) Change in mPAP from baseline. (B) Change in PVRI from baseline. (C) Change in mSAP from baseline. (D) Change in CI from baseline. CI = cardiac index; mPAP = mean pulmonary arterial pressure; mSAP = mean systemic arterial pressure; PVRI = pulmonary vascular resistance index; U50 = udenafil 50 mg; U100 = udenafil 100 mg.

• 

  Figure 2 Plotting of maximal PVRI change in udenafil on data from previous study by Ghofrani et al.9) Although plotted on different study subsets, change in maximal PVRI was greatest with U50, suggesting the highest selectivity of udenafil for pulmonary circulation, although udenafil is similar to sildenafil in molecular structure and is comparable in terms of PDE5 selectivity. PDE5 = phosphodiesterase-5; PVRI = pulmonary vascular resistance index; U50 = udenafil 50 mg; U100 = udenafil 100 mg.

Reference

1. Zhao C, Kim SW, Yang DY, et al. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2011; 60:380–387.

2. Park HJ, Park JK, Park K, Min K, Park NC. Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial. J Sex Med. 2010; 7:2209–2216.

3. Kim BH, Lim HS, Chung JY, et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol. 2008; 65:848–854.

4. Kim HL, Kim YJ, Kim KH, et al. Therapeutic effects of udenafil on pressure-overload cardiac hypertrophy. Hypertens Res. 2015; 38:597–604.

5. Kim KH, Kim HK, Hwang IC, et al. PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; a 12-week, randomized, double-blind, placebo-controlled trial. Am Heart J. 2015; 169:813–822.e3.

6. Kreisel W, Deibert P, Kupcinskas L, et al. The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. Dig Liver Dis. 2015; 47:144–150.

7. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353:2148–2157.

8. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009; 119:2894–2903.

9. Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol. 2004; 44:1488–1496.

10. Paick JS, Kim SW, Yang DY, et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med. 2008; 5:946–953.

11. Salem EA, Kendirci M, Hellstrom WJ. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Investig Drugs. 2006; 7:661–669.

12. Kim TE, Kim BH, Kim JR, et al. Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol. 2009; 68:43–46.

13. Fitzgerald AA, Powers JD, Ho PM, et al. Impact of medication nonadherence on hospitalizations and mortality in heart failure. J Card Fail. 2011; 17:664–669.

14. Frishman WH. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol Rev. 2007; 15:257–263.